A brief review on high on-aspirin residual platelet reactivity

Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been name...

Full description

Saved in:
Bibliographic Details
Published inVascular pharmacology Vol. 67-69; pp. 6 - 9
Main Authors Pettersen, A.A., Arnesen, H., Seljeflot, I.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2015
Subjects
Animals
Aspirin
Aspirin - adverse effects
Aspirin - pharmacology
Blood Platelets - drug effects
Blood Platelets - metabolism
Cardiovascular
Cardiovascular Diseases - blood
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Coronary artery disease
Cyclooxygenase
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Humans
Platelet Activation - drug effects
Platelet Activation - physiology
Platelet Aggregation - drug effects
Platelet Aggregation - physiology
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - pharmacology
Platelet Function Tests - methods
Platelet reactivity
Thromboxane
Aspirin
Cyclooxygenase
Thromboxane
Platelet reactivity
Coronary artery disease
Online AccessGet full text
ISSN1537-1891
1879-3649
DOI10.1016/j.vph.2015.03.018

Cover

Abstract Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been named aspirin resistance, aspirin non-responsiveness or high-on-aspirin residual platelet reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on aspirin have a very low level of serum thromboxane B2, indicating that the measured platelet reactivity in aspirin-treated patients might be due to platelet activation via other pathways, such as ADP or thrombin. The prevalence of real aspirin resistance seems to be very low, and probably the term “high-on-aspirin residual platelet reactivity” should be preferred to describe this phenomenon. [Display omitted]
AbstractList Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been named aspirin resistance, aspirin non-responsiveness or high-on-aspirin residual platelet reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on aspirin have a very low level of serum thromboxane B2, indicating that the measured platelet reactivity in aspirin-treated patients might be due to platelet activation via other pathways, such as ADP or thrombin. The prevalence of real aspirin resistance seems to be very low, and probably the term “high-on-aspirin residual platelet reactivity” should be preferred to describe this phenomenon. [Display omitted]
Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been named aspirin resistance, aspirin non-responsiveness or high-on-aspirin residual platelet reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on aspirin have a very low level of serum thromboxane B2, indicating that the measured platelet reactivity in aspirin-treated patients might be due to platelet activation via other pathways, such as ADP or thrombin. The prevalence of real aspirin resistance seems to be very low, and probably the term "high-on-aspirin residual platelet reactivity" should be preferred to describe this phenomenon.
Abstract Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In trials on aspirin-treated patients, platelet function tests have revealed large variability in platelet aggregation. This phenomenon has been named aspirin resistance, aspirin non-responsiveness or high-on-aspirin residual platelet reactivity. The mechanism of aspirin antiplatelet effect is due to the inhibition of cyclooxygenase-1 enzyme in platelets. In some trials, almost all patients on aspirin have a very low level of serum thromboxane B2 , indicating that the measured platelet reactivity in aspirin-treated patients might be due to platelet activation via other pathways, such as ADP or thrombin. The prevalence of real aspirin resistance seems to be very low, and probably the term “high-on-aspirin residual platelet reactivity” should be preferred to describe this phenomenon.
Author Arnesen, H.
Seljeflot, I.
Pettersen, A.A.
Author_xml – sequence: 1
  givenname: A.A.
  orcidid: 0000-0001-7543-475X
  surname: Pettersen
  fullname: Pettersen, A.A.
  email: alfaage@online.no
  organization: Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevaal, Norway
– sequence: 2
  givenname: H.
  surname: Arnesen
  fullname: Arnesen, H.
  organization: Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevaal, Norway
– sequence: 3
  givenname: I.
  surname: Seljeflot
  fullname: Seljeflot, I.
  organization: Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevaal, Norway
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25869498$$D View this record in MEDLINE/PubMed
BookMark eNqFkd1KxDAQhYMo_j-AN9IXaJ00mzRBEET8A8EL9Tpkk9SdtbYlya7s25tl9UZQr06YzDnDfHNAtvuh94ScUKgoUHE2r5bjrKqB8gpYBVRukX0qG1UyMVHb-c1ZU1Kp6B45iHEOuUMKtUv2ap51ouQ-ubgspgF9WwS_RP9RDH0xw9dZ1tLEEQP2-SeiW5iuGDuTfOdTrhibcIlpdUR2WtNFf_ylh-Tl5vr56q58eLy9v7p8KC2vZSpr5gyHZtIysFSYSR7OppYxJThVXHAH0uUSSMpb5gVXTVsrsCDqWjhjHTskp5vccTF9906PAd9NWOnvRXJDs2mwYYgx-FZbTCbh0KdgsNMU9BqZnuuMTK-RaWA6A8lO-sP5Hf6X53zj8XnnzC3oaNH31jsM3ibtBvzTffHDbTvs0Zruza98nA-L0GeYmupYa9BP6zOur0g5AAjJcoD6PeCf4Z9SwKo4
CitedBy_id crossref_primary_10_3390_jcm10173946
crossref_primary_10_1016_j_ajog_2020_05_026
crossref_primary_10_1161_STROKEAHA_116_013340
crossref_primary_10_2459_JCM_0000000000001406
crossref_primary_10_1007_s11906_016_0688_8
crossref_primary_10_1016_j_phrs_2020_105031
crossref_primary_10_2217_rme_2018_0133
crossref_primary_10_12968_hmed_2024_0370
crossref_primary_10_1080_09537104_2018_1557614
crossref_primary_10_1155_2016_2096181
crossref_primary_10_1186_s12967_016_0827_7
crossref_primary_10_1186_s12906_023_04112_7
crossref_primary_10_23939_ctas2023_01_099
crossref_primary_10_1055_s_0043_1769105
crossref_primary_10_1016_j_gene_2017_04_041
crossref_primary_10_1186_s12959_017_0151_3
crossref_primary_10_1038_ejcn_2016_222
crossref_primary_10_1186_s12877_021_02018_y
crossref_primary_10_1016_j_ejim_2015_12_003
crossref_primary_10_1111_jvp_12725
crossref_primary_10_1016_j_thromres_2023_11_014
crossref_primary_10_1097_MBC_0000000000000658
crossref_primary_10_1111_jsap_12776
Cites_doi 10.3109/00498258609043527
10.1016/S0140-6736(49)91829-2
10.1161/CIRCULATIONAHA.111.085464
10.1160/TH08-01-0056
10.1136/bmj.324.7329.71
10.1016/0049-3848(91)90085-B
10.1111/j.1742-1241.2006.01063.x
10.1161/01.STR.0000231683.43347.ec
10.1161/JAHA.112.000703
10.1016/j.amjcard.2004.12.038
10.1111/j.2042-7158.1989.tb06487.x
10.1080/00365510701601673
10.1016/j.thromres.2003.12.005
10.1016/j.jacc.2008.10.047
10.1073/pnas.112202999
10.1016/0049-3848(93)90164-J
10.1161/01.STR.24.3.345
10.1046/j.1538-7836.2003.00354.x
10.1016/S0735-1097(02)03014-0
10.1016/S0140-6736(09)60503-1
10.1016/j.ijcard.2014.05.013
10.1016/j.thromres.2008.12.034
10.1056/NEJMoa003199
10.1016/j.thromres.2007.04.010
10.1016/j.ahj.2006.10.040
10.1111/j.1538-7836.2008.02897.x
10.1111/j.1538-7836.2007.02387.x
10.1160/TH05-04-0889
10.1182/asheducation-2007.1.114
10.1016/0049-3848(80)90066-3
10.1016/j.amjcard.2006.05.041
10.1016/j.thromres.2005.10.011
10.1038/newbio231232a0
10.1016/j.jacc.2005.01.045
10.1161/01.STR.25.12.2331
10.1161/CIRCULATIONAHA.105.596627
10.1136/bmj.39430.529549.BE
10.1160/TH09-08-0527
10.1111/j.1538-7836.2005.01351.x
10.1001/archinte.167.15.1593
10.1172/JCI109332
10.1016/j.amjmed.2005.03.041
10.1056/NEJM198411083111902
10.1093/eurheartj/ehm226
10.1160/TH05-10-0653
10.1172/JCI109379
10.1016/S0021-9258(19)68855-1
10.1016/j.ehj.2003.10.013
10.1016/0002-9149(91)90379-Y
10.1182/blood.V69.1.180.180
10.1093/eurheartj/ehr373
10.1160/TH08-03-0186
10.1016/0304-4165(89)90051-2
10.1016/j.jacc.2005.05.090
10.1136/hrt.2008.150631
10.1160/TH10-02-0082
ContentType Journal Article
Copyright 2015 Elsevier Inc.
Elsevier Inc.
Copyright © 2015 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2015 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/j.vph.2015.03.018
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1879-3649
EndPage 9
ExternalDocumentID 25869498
10_1016_j_vph_2015_03_018
S1537189115000683
1_s2_0_S1537189115000683
Genre Journal Article
Review
GroupedDBID ---
--K
--M
-RU
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
4.4
457
4G.
53G
5VS
7-5
71M
8P~
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFRF
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ABZDS
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
M41
MO0
N9A
O-L
O9-
OAUVE
OA~
OGGZJ
OL0
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSZ
T5K
UHS
UNMZH
Z5R
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
SSP
AAIAV
AATCM
ABLVK
ABYKQ
AJBFU
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-c528t-23da5074f30c16a46943bc3396519565d08d9430815f3e6597f290c06226dacd3
IEDL.DBID .~1
ISSN 1537-1891
IngestDate Thu Apr 03 07:06:25 EDT 2025
Thu Apr 24 23:01:00 EDT 2025
Tue Jul 01 02:36:42 EDT 2025
Fri Feb 23 02:24:41 EST 2024
Sun Feb 23 10:20:48 EST 2025
Tue Aug 26 16:33:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Aspirin
Cyclooxygenase
Thromboxane
Platelet reactivity
Coronary artery disease
Language English
License Copyright © 2015 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-23da5074f30c16a46943bc3396519565d08d9430815f3e6597f290c06226dacd3
ORCID 0000-0001-7543-475X
PMID 25869498
PageCount 4
ParticipantIDs pubmed_primary_25869498
crossref_citationtrail_10_1016_j_vph_2015_03_018
crossref_primary_10_1016_j_vph_2015_03_018
elsevier_sciencedirect_doi_10_1016_j_vph_2015_03_018
elsevier_clinicalkeyesjournals_1_s2_0_S1537189115000683
elsevier_clinicalkey_doi_10_1016_j_vph_2015_03_018
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-04-01
PublicationDateYYYYMMDD 2015-04-01
PublicationDate_xml – month: 04
  year: 2015
  text: 2015-04-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Vascular pharmacology
PublicationTitleAlternate Vascul Pharmacol
PublicationYear 2015
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Pettersen, Seljeflot, Abdelnoor, Arnesen (bb0305) 2012; 1
Krasopoulos, Brister, Beattie, Buchanan (bb0005) 2008; 336
Catella-Lawson, Reilly, Kapoor, Cucchiara, DeMarco, Tournier (bb0245) 2001; 345
Williams, Mutch, Nicholson, Wynne, Wright, Lambert (bb0105) 1989; 41
Henry, Vermillet, Boval, Guyetand, Petroni, Dillinger (bb0230) 2011; 105
Michelson, Cattaneo, Eikelboom, Gurbel, Kottke-Marchant, Kunicki (bb0280) 2005; 3
Rocca, Secchiero, Ciabattoni, Ranelletti, Catani, Guidotti (bb0225) 2002; 99
Meen, Brosstad, Khiabani, Gjertsen, Lauritsen, Pedersen (bb0275) 2008; 68
Vane (bb0080) 1971; 231
Patrono, Andreotti, Arnesen, Badimon, Baigent, Collet (bb0055) 2011; 32
Patrono, Ciabattoni, Pinca, Pugliese, Castrucci, De Salvo (bb0095) 1980; 17
Gibson (bb0070) 1949; 2
Hillarp (bb0260) 2004; 101
Reilly, FitzGerald (bb0185) 1987; 69
FitzGerald (bb0120) 1991; 68
Snoep, Hovens, Eikenboom, van der Bom, Huisman (bb0010) 2007; 167
Wurtz, Hvas, Jensen, Kaltoft, Tilsted, Kristensen (bb0235) 2014; 175
Guthikonda, Lev, Patel, DeLao, Bergeron, Dong (bb0220) 2007; 5
Schwartz, Schwartz, Ghosheh, Reeves, Barber, DeFranco (bb0270) 2005; 95
Jaffe, Weksler (bb0130) 1979; 63
Hillarp, Palmqvist, Lethagen, Villoutreix, Mattiasson (bb0265) 2003; 112
Cox, Maree, Dooley, Conroy, Byrne, Fitzgerald (bb0085) 2006; 37
Pedersen, FitzGerald (bb0090) 1984; 311
De Gaetano, Cerletti (bb0035) 2003; 1
Czervionke, Smith, Fry, Hoak, Haycraft (bb0125) 1979; 63
Gianetti, Parri, Sbrana, Paoli, Maffei, Paradossi (bb0040) 2006; 118
Tantry, Bliden, Gurbel (bb0300) 2005; 46
Reny, De Moerloose, Dauzat, Fontana (bb0310) 2008; 6
Perneby, Wallen, Rooney, Fitzgerald, Hjemdahl (bb0115) 2006; 95
Helgason, Tortorice, Winkler, Penney, Schuler, McClelland (bb0150) 1993; 24
Reny, Berdague, Poncet, Barazer, Nolli, Fabbro-Peray (bb0315) 2012; 125
Lee, Chen, Ng, Cheng, Kwok, Tse (bb0205) 2005; 118
Grotemeyer, Scharafinski, Husstedt (bb0145) 1993; 71
Grove, Hvas, Kristensen (bb0215) 2009; 101
Marcucci, Paniccia, Antonucci, Gori, Fedi, Giglioli (bb0050) 2006; 98
Hovens, Snoep, Eikenboom, van der Bom, Mertens, Huisman (bb0295) 2007; 153
Lordkipanidze, Pharand, Schampaert, Turgeon, Palisaitis, Diodati (bb0175) 2007; 28
Craven (bb0060) 1953; 75
Fitzgerald, Maree (bb0250) 2007
Smith, DeWitt, Shimokawa, Kraemer, Meade (bb0075) 1990; 21
Coller (bb0160) 1979
Patrono, Bachmann, Baigent, Bode, De Caterina, Charbonnier (bb0025) 2004; 25
von Pape, Strupp, Bonzel, Bohner (bb0210) 2005; 94
Santilli, Rocca, De Cristofaro, Lattanzio, Pietrangelo, Habib (bb0190) 2009; 53
Capone, Sciulli, Tacconelli, Grana, Ricciotti, Renda (bb0240) 2005; 45
Zimmermann, Hohlfeld (bb0015) 2008; 100
Helgason, Bolin, Hoff, Winkler, Mangat, Tortorice (bb0155) 1994; 25
Chakroun, Addad, Abderazek, Ben-Farhat, Hamdi, Gamra (bb0165) 2007; 121
Roberts, Sweetman, Oates (bb0200) 1981; 256
Hutt, Caldwell, Smith (bb0110) 1986; 16
Grotemeyer (bb0140) 1991; 63
Collaboration (bb0030) 2002; 324
Muir, McMullin, Patterson, McKeown (bb0180) 2009; 95
Frelinger, Furman, Linden, Li, Fox, Barnard (bb0285) 2006; 113
Spenney (bb0100) 1978; 234
Malinin, Ong, Makarov, Petukhova, Serebruany (bb0255) 2006; 60
Baigent, Blackwell, Collins, Emberson, Godwin, Peto (bb0020) 2009; 373
Grove, Hvas, Johnsen, Hedegaard, Pedersen, Mortensen (bb0170) 2010; 103
Craven (bb0065) 1956; 78
Doroszko, Szahidewicz-Krupska, Janus, Jakubowski, Turek, Ilnicka (bb0135) 2015; 2
Gum, Kottke-Marchant, Welsh, White, Topol (bb0045) 2003; 41
Ciabattoni, Pugliese, Davi, Pierucci, Simonetti, Patrono (bb0195) 1989; 992
Hedegaard, Hvas, Grove, Refsgaard, Rocca, Davi (bb0290) 2009; 124
Gibson (10.1016/j.vph.2015.03.018_bb0070) 1949; 2
Rocca (10.1016/j.vph.2015.03.018_bb0225) 2002; 99
Grotemeyer (10.1016/j.vph.2015.03.018_bb0140) 1991; 63
Meen (10.1016/j.vph.2015.03.018_bb0275) 2008; 68
Tantry (10.1016/j.vph.2015.03.018_bb0300) 2005; 46
Perneby (10.1016/j.vph.2015.03.018_bb0115) 2006; 95
Lordkipanidze (10.1016/j.vph.2015.03.018_bb0175) 2007; 28
Wurtz (10.1016/j.vph.2015.03.018_bb0235) 2014; 175
Patrono (10.1016/j.vph.2015.03.018_bb0055) 2011; 32
Grove (10.1016/j.vph.2015.03.018_bb0170) 2010; 103
Czervionke (10.1016/j.vph.2015.03.018_bb0125) 1979; 63
Coller (10.1016/j.vph.2015.03.018_bb0160) 1979
Hovens (10.1016/j.vph.2015.03.018_bb0295) 2007; 153
De Gaetano (10.1016/j.vph.2015.03.018_bb0035) 2003; 1
Reilly (10.1016/j.vph.2015.03.018_bb0185) 1987; 69
Doroszko (10.1016/j.vph.2015.03.018_bb0135) 2015; 2
Capone (10.1016/j.vph.2015.03.018_bb0240) 2005; 45
Frelinger (10.1016/j.vph.2015.03.018_bb0285) 2006; 113
Williams (10.1016/j.vph.2015.03.018_bb0105) 1989; 41
Grotemeyer (10.1016/j.vph.2015.03.018_bb0145) 1993; 71
Baigent (10.1016/j.vph.2015.03.018_bb0020) 2009; 373
Michelson (10.1016/j.vph.2015.03.018_bb0280) 2005; 3
Roberts (10.1016/j.vph.2015.03.018_bb0200) 1981; 256
Lee (10.1016/j.vph.2015.03.018_bb0205) 2005; 118
Hedegaard (10.1016/j.vph.2015.03.018_bb0290) 2009; 124
Jaffe (10.1016/j.vph.2015.03.018_bb0130) 1979; 63
Cox (10.1016/j.vph.2015.03.018_bb0085) 2006; 37
Krasopoulos (10.1016/j.vph.2015.03.018_bb0005) 2008; 336
Pedersen (10.1016/j.vph.2015.03.018_bb0090) 1984; 311
Gianetti (10.1016/j.vph.2015.03.018_bb0040) 2006; 118
Helgason (10.1016/j.vph.2015.03.018_bb0150) 1993; 24
Collaboration (10.1016/j.vph.2015.03.018_bb0030) 2002; 324
von Pape (10.1016/j.vph.2015.03.018_bb0210) 2005; 94
Hutt (10.1016/j.vph.2015.03.018_bb0110) 1986; 16
Muir (10.1016/j.vph.2015.03.018_bb0180) 2009; 95
Vane (10.1016/j.vph.2015.03.018_bb0080) 1971; 231
Santilli (10.1016/j.vph.2015.03.018_bb0190) 2009; 53
Spenney (10.1016/j.vph.2015.03.018_bb0100) 1978; 234
Reny (10.1016/j.vph.2015.03.018_bb0315) 2012; 125
Smith (10.1016/j.vph.2015.03.018_bb0075) 1990; 21
Patrono (10.1016/j.vph.2015.03.018_bb0025) 2004; 25
Schwartz (10.1016/j.vph.2015.03.018_bb0270) 2005; 95
Hillarp (10.1016/j.vph.2015.03.018_bb0260) 2004; 101
Chakroun (10.1016/j.vph.2015.03.018_bb0165) 2007; 121
FitzGerald (10.1016/j.vph.2015.03.018_bb0120) 1991; 68
Grove (10.1016/j.vph.2015.03.018_bb0215) 2009; 101
Zimmermann (10.1016/j.vph.2015.03.018_bb0015) 2008; 100
Pettersen (10.1016/j.vph.2015.03.018_bb0305) 2012; 1
Reny (10.1016/j.vph.2015.03.018_bb0310) 2008; 6
Helgason (10.1016/j.vph.2015.03.018_bb0155) 1994; 25
Henry (10.1016/j.vph.2015.03.018_bb0230) 2011; 105
Gum (10.1016/j.vph.2015.03.018_bb0045) 2003; 41
Ciabattoni (10.1016/j.vph.2015.03.018_bb0195) 1989; 992
Craven (10.1016/j.vph.2015.03.018_bb0060) 1953; 75
Catella-Lawson (10.1016/j.vph.2015.03.018_bb0245) 2001; 345
Snoep (10.1016/j.vph.2015.03.018_bb0010) 2007; 167
Guthikonda (10.1016/j.vph.2015.03.018_bb0220) 2007; 5
Patrono (10.1016/j.vph.2015.03.018_bb0095) 1980; 17
Marcucci (10.1016/j.vph.2015.03.018_bb0050) 2006; 98
Hillarp (10.1016/j.vph.2015.03.018_bb0265) 2003; 112
Craven (10.1016/j.vph.2015.03.018_bb0065) 1956; 78
Fitzgerald (10.1016/j.vph.2015.03.018_bb0250) 2007
Malinin (10.1016/j.vph.2015.03.018_bb0255) 2006; 60
References_xml – volume: 1
  start-page: 2048
  year: 2003
  end-page: 2050
  ident: bb0035
  article-title: Aspirin resistance: a revival of platelet aggregation tests?
  publication-title: J Thromb Haemost
– volume: 60
  start-page: 993
  year: 2006
  end-page: 1002
  ident: bb0255
  article-title: Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors
  publication-title: Int J Clin Pract
– volume: 1
  start-page: e000703
  year: 2012
  ident: bb0305
  article-title: High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
  publication-title: J Am Heart Assoc
– volume: 2
  start-page: 1172
  year: 1949
  end-page: 1174
  ident: bb0070
  article-title: Aspirin in the treatment of vascular diseases
  publication-title: Lancet
– volume: 46
  start-page: 1705
  year: 2005
  end-page: 1709
  ident: bb0300
  article-title: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
  publication-title: J Am Coll Cardiol
– volume: 68
  start-page: 11B
  year: 1991
  end-page: 15B
  ident: bb0120
  article-title: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists
  publication-title: Am J Cardiol
– volume: 25
  start-page: 166
  year: 2004
  end-page: 181
  ident: bb0025
  article-title: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
  publication-title: Eur Heart J
– volume: 103
  start-page: 1245
  year: 2010
  end-page: 1253
  ident: bb0170
  article-title: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
  publication-title: Thromb Haemost
– volume: 100
  start-page: 379
  year: 2008
  end-page: 390
  ident: bb0015
  article-title: Clinical implications of aspirin resistance
  publication-title: Thromb Haemost
– volume: 231
  start-page: 232
  year: 1971
  end-page: 235
  ident: bb0080
  article-title: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
  publication-title: Nat New Biol
– volume: 98
  start-page: 1156
  year: 2006
  end-page: 1159
  ident: bb0050
  article-title: Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events
  publication-title: Am J Cardiol
– volume: 95
  start-page: 652
  year: 2006
  end-page: 658
  ident: bb0115
  article-title: Dose- and time-dependent antiplatelet effects of aspirin
  publication-title: Thromb Haemost
– volume: 101
  start-page: 151
  year: 2009
  end-page: 156
  ident: bb0215
  article-title: Immature platelets in patients with acute coronary syndromes
  publication-title: Thromb Haemost
– volume: 118
  start-page: 723
  year: 2005
  end-page: 727
  ident: bb0205
  article-title: Low-dose aspirin increases aspirin resistance in patients with coronary artery disease
  publication-title: Am J Med
– volume: 94
  start-page: 889
  year: 2005
  end-page: 891
  ident: bb0210
  article-title: Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction
  publication-title: Thromb Haemost
– volume: 2
  start-page: 001
  year: 2015
  ident: bb0135
  article-title: Endothelial dysfunction in young healthy men is associated with aspirin resistance
  publication-title: Vascul Pharmacol
– volume: 6
  start-page: 444
  year: 2008
  end-page: 450
  ident: bb0310
  article-title: Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis
  publication-title: J Thromb Haemost
– volume: 25
  start-page: 2331
  year: 1994
  end-page: 2336
  ident: bb0155
  article-title: Development of aspirin resistance in persons with previous ischemic stroke
  publication-title: Stroke
– volume: 3
  start-page: 1309
  year: 2005
  end-page: 1311
  ident: bb0280
  article-title: Aspirin resistance: position paper of the Working Group on Aspirin Resistance
  publication-title: J Thromb Haemost
– volume: 167
  start-page: 1593
  year: 2007
  end-page: 1599
  ident: bb0010
  article-title: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis
  publication-title: Arch Intern Med
– volume: 234
  start-page: E606
  year: 1978
  end-page: E610
  ident: bb0100
  article-title: Acetylsalicylic acid hydrolase of gastric mucosa
  publication-title: Am J Physiol
– volume: 95
  start-page: 1225
  year: 2009
  end-page: 1229
  ident: bb0180
  article-title: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease
  publication-title: Heart
– volume: 175
  start-page: 274
  year: 2014
  end-page: 279
  ident: bb0235
  article-title: 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis
  publication-title: Int J Cardiol
– volume: 41
  start-page: 407
  year: 1989
  end-page: 409
  ident: bb0105
  article-title: Human liver and plasma aspirin esterase
  publication-title: J Pharm Pharmacol
– start-page: 114
  year: 2007
  end-page: 120
  ident: bb0250
  article-title: Aspirin and clopidogrel resistance
  publication-title: Hematol Am Soc Hematol Educ Prog
– year: 1979
  ident: bb0160
  article-title: Platelet aggregation by ADP, collagen and ristocetin: a critical review of methodology and analysis
– volume: 121
  start-page: 413
  year: 2007
  end-page: 418
  ident: bb0165
  article-title: Screening for aspirin resistance in stable coronary artery patients by three different tests
  publication-title: Thromb Res
– volume: 75
  start-page: 38
  year: 1953
  end-page: 44
  ident: bb0060
  article-title: Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis
  publication-title: Miss Valley Med J
– volume: 124
  start-page: 96
  year: 2009
  end-page: 100
  ident: bb0290
  article-title: Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration
  publication-title: Thromb Res
– volume: 16
  start-page: 239
  year: 1986
  end-page: 249
  ident: bb0110
  article-title: The metabolism of aspirin in man: a population study
  publication-title: Xenobiotica
– volume: 28
  start-page: 1702
  year: 2007
  end-page: 1708
  ident: bb0175
  article-title: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  publication-title: Eur Heart J
– volume: 125
  start-page: 3201
  year: 2012
  end-page: 3210
  ident: bb0315
  article-title: Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study
  publication-title: Circulation
– volume: 69
  start-page: 180
  year: 1987
  end-page: 186
  ident: bb0185
  article-title: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
  publication-title: Blood
– volume: 99
  start-page: 7634
  year: 2002
  end-page: 7639
  ident: bb0225
  article-title: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
  publication-title: Proc Natl Acad Sci U S A
– volume: 21
  start-page: IV24
  year: 1990
  end-page: IV28
  ident: bb0075
  article-title: Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents
  publication-title: Stroke
– volume: 63
  start-page: 532
  year: 1979
  end-page: 535
  ident: bb0130
  article-title: Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin
  publication-title: J Clin Invest
– volume: 41
  start-page: 961
  year: 2003
  end-page: 965
  ident: bb0045
  article-title: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
  publication-title: J Am Coll Cardiol
– volume: 63
  start-page: 1089
  year: 1979
  end-page: 1092
  ident: bb0125
  article-title: Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence
  publication-title: J Clin Invest
– volume: 63
  start-page: 587
  year: 1991
  end-page: 593
  ident: bb0140
  article-title: Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients
  publication-title: Thromb Res
– volume: 78
  start-page: 213
  year: 1956
  end-page: 215
  ident: bb0065
  article-title: Prevention of coronary and cerebral thrombosis
  publication-title: Miss Valley Med J
– volume: 32
  start-page: 2922
  year: 2011
  end-page: 2932
  ident: bb0055
  article-title: Antiplatelet agents for the treatment and prevention of atherothrombosis
  publication-title: Eur Heart J
– volume: 17
  start-page: 317
  year: 1980
  end-page: 327
  ident: bb0095
  article-title: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
  publication-title: Thromb Res
– volume: 992
  start-page: 66
  year: 1989
  end-page: 70
  ident: bb0195
  article-title: Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man
  publication-title: Biochim Biophys Acta
– volume: 345
  start-page: 1809
  year: 2001
  end-page: 1817
  ident: bb0245
  article-title: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
  publication-title: N Engl J Med
– volume: 118
  start-page: 487
  year: 2006
  end-page: 493
  ident: bb0040
  article-title: Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6
  publication-title: Thromb Res
– volume: 112
  start-page: 275
  year: 2003
  end-page: 283
  ident: bb0265
  article-title: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke
  publication-title: Thromb Res
– volume: 45
  start-page: 1295
  year: 2005
  end-page: 1301
  ident: bb0240
  article-title: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
  publication-title: J Am Coll Cardiol
– volume: 113
  start-page: 2888
  year: 2006
  end-page: 2896
  ident: bb0285
  article-title: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance
  publication-title: Circulation
– volume: 311
  start-page: 1206
  year: 1984
  end-page: 1211
  ident: bb0090
  article-title: Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase
  publication-title: N Engl J Med
– volume: 5
  start-page: 490
  year: 2007
  end-page: 496
  ident: bb0220
  article-title: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin
  publication-title: J Thromb Haemost
– volume: 256
  start-page: 8384
  year: 1981
  end-page: 8393
  ident: bb0200
  article-title: Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites
  publication-title: J Biol Chem
– volume: 37
  start-page: 2153
  year: 2006
  end-page: 2158
  ident: bb0085
  article-title: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers
  publication-title: Stroke
– volume: 153
  start-page: 175
  year: 2007
  end-page: 181
  ident: bb0295
  article-title: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review
  publication-title: Am Heart J
– volume: 336
  start-page: 195
  year: 2008
  end-page: 198
  ident: bb0005
  article-title: Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis
  publication-title: BMJ
– volume: 373
  start-page: 1849
  year: 2009
  end-page: 1860
  ident: bb0020
  article-title: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
  publication-title: Lancet
– volume: 53
  start-page: 667
  year: 2009
  end-page: 677
  ident: bb0190
  article-title: Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”
  publication-title: J Am Coll Cardiol
– volume: 24
  start-page: 345
  year: 1993
  end-page: 350
  ident: bb0150
  article-title: Aspirin response and failure in cerebral infarction
  publication-title: Stroke
– volume: 95
  start-page: 973
  year: 2005
  end-page: 975
  ident: bb0270
  article-title: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction
  publication-title: Am J Cardiol
– volume: 68
  start-page: 185
  year: 2008
  end-page: 191
  ident: bb0275
  article-title: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography
  publication-title: Scand J Clin Lab Invest
– volume: 71
  start-page: 397
  year: 1993
  end-page: 403
  ident: bb0145
  article-title: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients
  publication-title: Thromb Res
– volume: 324
  start-page: 71
  year: 2002
  end-page: 86
  ident: bb0030
  article-title: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  publication-title: BMJ
– volume: 105
  start-page: 336
  year: 2011
  end-page: 344
  ident: bb0230
  article-title: 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
  publication-title: Thromb Haemost
– volume: 101
  start-page: 3504
  year: 2004
  end-page: 3506
  ident: bb0260
  article-title: Acetylsalicylic acid resistance—clinical diagnosis with unclear mechanism
  publication-title: Lakartidningen
– volume: 78
  start-page: 213
  year: 1956
  ident: 10.1016/j.vph.2015.03.018_bb0065
  article-title: Prevention of coronary and cerebral thrombosis
  publication-title: Miss Valley Med J
– volume: 16
  start-page: 239
  year: 1986
  ident: 10.1016/j.vph.2015.03.018_bb0110
  article-title: The metabolism of aspirin in man: a population study
  publication-title: Xenobiotica
  doi: 10.3109/00498258609043527
– volume: 2
  start-page: 1172
  year: 1949
  ident: 10.1016/j.vph.2015.03.018_bb0070
  article-title: Aspirin in the treatment of vascular diseases
  publication-title: Lancet
  doi: 10.1016/S0140-6736(49)91829-2
– volume: 75
  start-page: 38
  year: 1953
  ident: 10.1016/j.vph.2015.03.018_bb0060
  article-title: Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis
  publication-title: Miss Valley Med J
– volume: 125
  start-page: 3201
  year: 2012
  ident: 10.1016/j.vph.2015.03.018_bb0315
  article-title: Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.111.085464
– volume: 100
  start-page: 379
  year: 2008
  ident: 10.1016/j.vph.2015.03.018_bb0015
  article-title: Clinical implications of aspirin resistance
  publication-title: Thromb Haemost
  doi: 10.1160/TH08-01-0056
– volume: 324
  start-page: 71
  year: 2002
  ident: 10.1016/j.vph.2015.03.018_bb0030
  article-title: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  publication-title: BMJ
  doi: 10.1136/bmj.324.7329.71
– volume: 63
  start-page: 587
  year: 1991
  ident: 10.1016/j.vph.2015.03.018_bb0140
  article-title: Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients
  publication-title: Thromb Res
  doi: 10.1016/0049-3848(91)90085-B
– volume: 60
  start-page: 993
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0255
  article-title: Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2006.01063.x
– volume: 37
  start-page: 2153
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0085
  article-title: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers
  publication-title: Stroke
  doi: 10.1161/01.STR.0000231683.43347.ec
– volume: 1
  start-page: e000703
  year: 2012
  ident: 10.1016/j.vph.2015.03.018_bb0305
  article-title: High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.112.000703
– volume: 101
  start-page: 3504
  year: 2004
  ident: 10.1016/j.vph.2015.03.018_bb0260
  article-title: Acetylsalicylic acid resistance—clinical diagnosis with unclear mechanism
  publication-title: Lakartidningen
– volume: 95
  start-page: 973
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0270
  article-title: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2004.12.038
– volume: 41
  start-page: 407
  year: 1989
  ident: 10.1016/j.vph.2015.03.018_bb0105
  article-title: Human liver and plasma aspirin esterase
  publication-title: J Pharm Pharmacol
  doi: 10.1111/j.2042-7158.1989.tb06487.x
– volume: 68
  start-page: 185
  year: 2008
  ident: 10.1016/j.vph.2015.03.018_bb0275
  article-title: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography
  publication-title: Scand J Clin Lab Invest
  doi: 10.1080/00365510701601673
– volume: 112
  start-page: 275
  year: 2003
  ident: 10.1016/j.vph.2015.03.018_bb0265
  article-title: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2003.12.005
– volume: 53
  start-page: 667
  year: 2009
  ident: 10.1016/j.vph.2015.03.018_bb0190
  article-title: Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2008.10.047
– volume: 99
  start-page: 7634
  year: 2002
  ident: 10.1016/j.vph.2015.03.018_bb0225
  article-title: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.112202999
– volume: 71
  start-page: 397
  year: 1993
  ident: 10.1016/j.vph.2015.03.018_bb0145
  article-title: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients
  publication-title: Thromb Res
  doi: 10.1016/0049-3848(93)90164-J
– volume: 24
  start-page: 345
  year: 1993
  ident: 10.1016/j.vph.2015.03.018_bb0150
  article-title: Aspirin response and failure in cerebral infarction
  publication-title: Stroke
  doi: 10.1161/01.STR.24.3.345
– volume: 1
  start-page: 2048
  year: 2003
  ident: 10.1016/j.vph.2015.03.018_bb0035
  article-title: Aspirin resistance: a revival of platelet aggregation tests?
  publication-title: J Thromb Haemost
  doi: 10.1046/j.1538-7836.2003.00354.x
– volume: 41
  start-page: 961
  year: 2003
  ident: 10.1016/j.vph.2015.03.018_bb0045
  article-title: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(02)03014-0
– volume: 373
  start-page: 1849
  year: 2009
  ident: 10.1016/j.vph.2015.03.018_bb0020
  article-title: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60503-1
– volume: 175
  start-page: 274
  year: 2014
  ident: 10.1016/j.vph.2015.03.018_bb0235
  article-title: 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2014.05.013
– volume: 124
  start-page: 96
  year: 2009
  ident: 10.1016/j.vph.2015.03.018_bb0290
  article-title: Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2008.12.034
– volume: 345
  start-page: 1809
  year: 2001
  ident: 10.1016/j.vph.2015.03.018_bb0245
  article-title: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa003199
– volume: 121
  start-page: 413
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0165
  article-title: Screening for aspirin resistance in stable coronary artery patients by three different tests
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2007.04.010
– volume: 153
  start-page: 175
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0295
  article-title: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2006.10.040
– volume: 6
  start-page: 444
  year: 2008
  ident: 10.1016/j.vph.2015.03.018_bb0310
  article-title: Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2008.02897.x
– volume: 5
  start-page: 490
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0220
  article-title: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2007.02387.x
– volume: 94
  start-page: 889
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0210
  article-title: Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction
  publication-title: Thromb Haemost
  doi: 10.1160/TH05-04-0889
– volume: 2
  start-page: 001
  year: 2015
  ident: 10.1016/j.vph.2015.03.018_bb0135
  article-title: Endothelial dysfunction in young healthy men is associated with aspirin resistance
  publication-title: Vascul Pharmacol
– start-page: 114
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0250
  article-title: Aspirin and clopidogrel resistance
  publication-title: Hematol Am Soc Hematol Educ Prog
  doi: 10.1182/asheducation-2007.1.114
– volume: 17
  start-page: 317
  year: 1980
  ident: 10.1016/j.vph.2015.03.018_bb0095
  article-title: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
  publication-title: Thromb Res
  doi: 10.1016/0049-3848(80)90066-3
– volume: 98
  start-page: 1156
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0050
  article-title: Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2006.05.041
– volume: 118
  start-page: 487
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0040
  article-title: Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6months prospective study
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2005.10.011
– volume: 231
  start-page: 232
  year: 1971
  ident: 10.1016/j.vph.2015.03.018_bb0080
  article-title: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
  publication-title: Nat New Biol
  doi: 10.1038/newbio231232a0
– volume: 45
  start-page: 1295
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0240
  article-title: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2005.01.045
– volume: 25
  start-page: 2331
  year: 1994
  ident: 10.1016/j.vph.2015.03.018_bb0155
  article-title: Development of aspirin resistance in persons with previous ischemic stroke
  publication-title: Stroke
  doi: 10.1161/01.STR.25.12.2331
– volume: 113
  start-page: 2888
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0285
  article-title: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.105.596627
– volume: 336
  start-page: 195
  year: 2008
  ident: 10.1016/j.vph.2015.03.018_bb0005
  article-title: Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis
  publication-title: BMJ
  doi: 10.1136/bmj.39430.529549.BE
– year: 1979
  ident: 10.1016/j.vph.2015.03.018_bb0160
– volume: 103
  start-page: 1245
  year: 2010
  ident: 10.1016/j.vph.2015.03.018_bb0170
  article-title: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease
  publication-title: Thromb Haemost
  doi: 10.1160/TH09-08-0527
– volume: 3
  start-page: 1309
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0280
  article-title: Aspirin resistance: position paper of the Working Group on Aspirin Resistance
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2005.01351.x
– volume: 167
  start-page: 1593
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0010
  article-title: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.167.15.1593
– volume: 63
  start-page: 532
  year: 1979
  ident: 10.1016/j.vph.2015.03.018_bb0130
  article-title: Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin
  publication-title: J Clin Invest
  doi: 10.1172/JCI109332
– volume: 118
  start-page: 723
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0205
  article-title: Low-dose aspirin increases aspirin resistance in patients with coronary artery disease
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2005.03.041
– volume: 311
  start-page: 1206
  year: 1984
  ident: 10.1016/j.vph.2015.03.018_bb0090
  article-title: Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198411083111902
– volume: 28
  start-page: 1702
  year: 2007
  ident: 10.1016/j.vph.2015.03.018_bb0175
  article-title: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehm226
– volume: 95
  start-page: 652
  year: 2006
  ident: 10.1016/j.vph.2015.03.018_bb0115
  article-title: Dose- and time-dependent antiplatelet effects of aspirin
  publication-title: Thromb Haemost
  doi: 10.1160/TH05-10-0653
– volume: 63
  start-page: 1089
  year: 1979
  ident: 10.1016/j.vph.2015.03.018_bb0125
  article-title: Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence
  publication-title: J Clin Invest
  doi: 10.1172/JCI109379
– volume: 256
  start-page: 8384
  year: 1981
  ident: 10.1016/j.vph.2015.03.018_bb0200
  article-title: Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)68855-1
– volume: 25
  start-page: 166
  year: 2004
  ident: 10.1016/j.vph.2015.03.018_bb0025
  article-title: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
  publication-title: Eur Heart J
  doi: 10.1016/j.ehj.2003.10.013
– volume: 68
  start-page: 11B
  year: 1991
  ident: 10.1016/j.vph.2015.03.018_bb0120
  article-title: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists
  publication-title: Am J Cardiol
  doi: 10.1016/0002-9149(91)90379-Y
– volume: 69
  start-page: 180
  year: 1987
  ident: 10.1016/j.vph.2015.03.018_bb0185
  article-title: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
  publication-title: Blood
  doi: 10.1182/blood.V69.1.180.180
– volume: 32
  start-page: 2922
  year: 2011
  ident: 10.1016/j.vph.2015.03.018_bb0055
  article-title: Antiplatelet agents for the treatment and prevention of atherothrombosis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehr373
– volume: 21
  start-page: IV24
  year: 1990
  ident: 10.1016/j.vph.2015.03.018_bb0075
  article-title: Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents
  publication-title: Stroke
– volume: 101
  start-page: 151
  year: 2009
  ident: 10.1016/j.vph.2015.03.018_bb0215
  article-title: Immature platelets in patients with acute coronary syndromes
  publication-title: Thromb Haemost
  doi: 10.1160/TH08-03-0186
– volume: 992
  start-page: 66
  year: 1989
  ident: 10.1016/j.vph.2015.03.018_bb0195
  article-title: Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0304-4165(89)90051-2
– volume: 234
  start-page: E606
  year: 1978
  ident: 10.1016/j.vph.2015.03.018_bb0100
  article-title: Acetylsalicylic acid hydrolase of gastric mucosa
  publication-title: Am J Physiol
– volume: 46
  start-page: 1705
  year: 2005
  ident: 10.1016/j.vph.2015.03.018_bb0300
  article-title: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2005.05.090
– volume: 95
  start-page: 1225
  year: 2009
  ident: 10.1016/j.vph.2015.03.018_bb0180
  article-title: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease
  publication-title: Heart
  doi: 10.1136/hrt.2008.150631
– volume: 105
  start-page: 336
  year: 2011
  ident: 10.1016/j.vph.2015.03.018_bb0230
  article-title: 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
  publication-title: Thromb Haemost
  doi: 10.1160/TH10-02-0082
SSID ssj0018869
Score 2.240033
SecondaryResourceType review_article
Snippet Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen. In...
Abstract Although aspirin is effective in secondary prevention in coronary heart disease, new thromboembolic events in patients on aspirin are frequently seen....
SourceID pubmed
crossref
elsevier
SourceType Index Database
Enrichment Source
Publisher
StartPage 6
SubjectTerms Animals
Aspirin
Aspirin - adverse effects
Aspirin - pharmacology
Blood Platelets - drug effects
Blood Platelets - metabolism
Cardiovascular
Cardiovascular Diseases - blood
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Coronary artery disease
Cyclooxygenase
Endothelium, Vascular - drug effects
Endothelium, Vascular - metabolism
Humans
Platelet Activation - drug effects
Platelet Activation - physiology
Platelet Aggregation - drug effects
Platelet Aggregation - physiology
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - pharmacology
Platelet Function Tests - methods
Platelet reactivity
Thromboxane
Title A brief review on high on-aspirin residual platelet reactivity
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1537189115000683
https://www.clinicalkey.es/playcontent/1-s2.0-S1537189115000683
https://dx.doi.org/10.1016/j.vph.2015.03.018
https://www.ncbi.nlm.nih.gov/pubmed/25869498
Volume 67-69
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwEA9DX3wRv50fIw-yB1ld2rRZ-yKM4ZiKY-AGewtpm8JkdMVOYS_-7d71a4oywafSNNe0l8vljtz9jpArpYMQdi3XCLinwUGJmOEJyzaEpZUIfe2prBjM01AMJvbD1JnWSK_MhcGwykL35zo909ZFS7vgZjuZzdrPsFZBsXpo0mCiAyJ-InodyPTNRxXmYbpuVtYOOxvYuzzZzGK83hM8jzCdDOcU635s3Ju-bDz9PbJbWIy0m3_UPqnp-IA0Rznk9KpFx-sMqrRFm3S0BqNeHZLbLvXBG45onqNCFzFFhGK4GgoP2WcxPEmzjCyazMHwhHmEFkx3wKoSR2TSvxv3BkZRM8EIHMtdGhYPFZh4dsRZYAoFzq_N_YBzTyCMjHBC5oaIuO6aTsS1AHcisjwWMAFmWKiCkB-TrXgR61NCQ42UbsfHcr6mNj0FuqGDFmPEVKRVnbCSWzIoAMWxrsVclpFjLxIYLJHBknEJDK6T64okydE0NnW2yimQZZooKDYJun4TUec3Ip0WSzOVpkwtyeQP8akTu6L8JoF_DXiSS0f1Q5YDImd77tn_XnhOdvAujw66IFvL1zd9CYbP0m9kkt0g2937x8HwE1em_zw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5qe9CL-LY-9yAexNBNNtkmF6GI0lotghW8LZtkAxWJxVSh_96ZPFpFqeApsNnJY3Z2doaZ-QbgRJsoxlPLtyIRGHRQEm4F0nEt6Rgt49AEOm8GczeQ3Uf35sl7qsFlVQtDaZWl7i90eq6ty5FWyc3WeDRqPeBeRcUakElDhQ5iCRqETuXWodHp9buDWTDB9_POdjTfIoIquJmneX2MKSRheznUKbX-WHg8fTl7rtdgtTQaWaf4rnWomXQDTu8L1OnpORvOi6iyc3bK7ud41NNNuOiwEB3ihBVlKuw1ZQRSjFdLU5x9lOKdLC_KYuMXtD1xKXGEKh6oscQWPF5fDS-7Vtk2wYo8x59Yjog1WnluInhkS43-ryvCSIhAEpKM9GLuxwS67tteIoxEjyJxAh5xiZZYrKNYbEM9fU3NLrDYEKXfDqmjr23sQKN6aJPRmHCdGN0EXnFLRSWmOLW2eFFV8tizQgYrYrDiQiGDm3A2IxkXgBqLJjvVEqiqUhR1m0J1v4io_RuRycrdmSlbZY7i6ocENcGdUX4Twr9euFNIx-yHHA9Fzg38vf898BiWu8O7W3XbG_T3YYXuFMlCB1CfvL2bQ7SDJuFRKeefGhAB_A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+brief+review+on+high+on-aspirin+residual+platelet+reactivity&rft.jtitle=Vascular+pharmacology&rft.au=Pettersen%2C+A.A&rft.au=Arnesen%2C+H&rft.au=Seljeflot%2C+I&rft.date=2015-04-01&rft.issn=1537-1891&rft.volume=67&rft.spage=6&rft.epage=9&rft_id=info:doi/10.1016%2Fj.vph.2015.03.018&rft.externalDBID=ECK1-s2.0-S1537189115000683&rft.externalDocID=1_s2_0_S1537189115000683
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15371891%2FS1537189115X00048%2Fcov150h.gif